H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target
$CLDI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00